About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Enrolling By InvitationEARLY Phase 1NCT07023068

⁶⁸Ga-DPA in the Lung Cancer Diagnosis

In previous studies, we synthesized a PD-L1-targeted molecular probe, ⁶⁸Ga-DPA, and developed a ⁶⁸Ga-DPA injection for clinical research. Preliminary studies demonstrated its favorable safety profile ...

Lead sponsor: Peking Union Medical College Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Peking Union Medical College Hospital

Age

18 - 85 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Age ≥18 years, regardless of gender.
•Patients clinically confirmed or suspected of lung cancer, with pathological specimens obtainable via biopsy or surgery within the recent 2 months.
•At least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
•Expected survival \>3 months.

Exclusion Criteria

•Severe hepatic or renal dysfunction (serum creatinine \>3.0 mg/dL or any liver enzyme level ≥5× upper limit of normal).
•Women who are planning pregnancy, pregnant, or breastfeeding.
•Inability to lie supine for 30 minutes.
•Claustrophobia or other psychiatric disorders.
•Intolerance to any clinical procedures in the study.
•Other conditions deemed ineligible by the investigator.

Related studies

The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]

NCT02688894 · Small Cell Lung Cancers, Neuroendocrine Carcinoma

Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers

NCT06816121 · Lung Cancers

RECRUITINGPhase 3

Erector Spinae Versus Intercostal Nerve Blocks With Liposomal Bupivacaine for Analgesia in Thoracic Surgery

NCT06810375 · Lung Cancers

Multi-omics Study of Early-stage Lung Cancer With Distinct Phenotypes

NCT06699979 · Lung Cancer Associated With Cystic Airspaces, Multiple Primary Lung Cancers, and more

Precision Lung Cancer Survivorship Care Intervention

NCT05857995 · Lung Cancer, Pulmonary Neoplasm, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 15, 2025Terms

Trial snapshot

StatusENROLLING_BY_INVITATION

PhaseEARLY_PHASE1

Enrollment40

Start dateSep 2024

Last updatedJun 15, 2025

Condition

Locations shown

100730

Beijing

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 15, 2025Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions